Korean J Med.  1998 Nov;55(5):868-873.

Evaluation of Clinicopathologic and Prognostic Significance of nm23 protein in stage III Gastric Adenocarcinoma

• Han DH
• Oh HT
• Lee DS
• Kim SY
• Ahn BY
• Joo MJ
• Lee KM
• Lee JM
• Shin SH
• Kim MC

Abstract

OBJECTIVE
Gene expression of nm23 has been investigated in a number of tumors, including breast cancer, colon cancer, malignant melanoma, and hepatocellular carcinoma. Its down-regulation has been shown to be associated with metastasis or disease progression in some of the tumors. This study was carried out to define the relationship between nm23 protein expression and clinicopathological variables.
METHODS
nm23 protein levels were investigated in 64 surgically resected specimens of stage III gastric cancer by immunohistochemical method, and association with clinicopathological parameters and survival rates were determined.
RESULTS
The overall expression rates of nm23 was 68.7 %. There was no significant difference between nm23 protein expression and clinicopathological variables such as age, sex, stage, histology, tumor depth, number of metastatic nodes, tumor size, site and method of operation. Statistically, no significant differences between nm23 protein expression and overall survival rates were found.
CONCLUSIONS
These results suggest that nm23 protein expression is an unsatisfactory prognostic indicator in stage III gastric adenocarcinoma.

Keyword

stage III gastric adenocarcinoma; nm23 protein

MeSH Terms

Adenocarcinoma*
Breast Neoplasms
Carcinoma, Hepatocellular
Colonic Neoplasms
Disease Progression
Down-Regulation
Gene Expression
Melanoma
Neoplasm Metastasis
Stomach Neoplasms
Survival Rate